Octreotide is a somatostatin peptide analog that acts at somatostatin receptors and inhibits the release of growth hormone. Octreotide exhibits anticancer, anti-fibrotic, anti-inflammatory, and immunomodulatory activities. Octreotide inhibits colon cancer cell growth through the suppression of Wnt/β-catenin signaling. Octreotide inhibits hepatic stellate cell proliferation, downregulating the expression of TGF-β, α-SMA, Smad-4a, c-Jun, sp-1, ET-1, and collagen; it is also protective against fibrosis in animal models. Additionally, octreotide inhibits peripheral blood mononuclear cell proliferation, decreasing levels of IL-6, IL-10, and IFN-γ and producing clinical improvements in subjects with systematic lupus erythematous.
References
Wang S, Bao Z, Liang QM, et al. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator. Hepatogastroenterology. 2013 Oct;60(127):1639-46. PMID: 24634935.
Wang J, Wang L, Song G, et al. The mechanism through which octreotide inhibits hepatic stellate cell activity. Mol Med Rep. 2013 May;7(5):1559-64. PMID: 23525276.
Tug T, Kara H, Karaoglu A, et al. The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats. Drug Chem Toxicol. 2013 Apr;36(2):181-6. PMID: 22946449.
Zhang Y, Huang W, Li F, et al. Octreotide for the treatment of systemic lupus erythematosus: clinical effects and an in vitro study on its therapeutic mechanism. Lupus. 2011 Oct;20(11):1172-81. PMID: 21979989.